Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:02:18 2024-09-10 pm EDT			5-day change	1st Jan Change
29.74 ^USD	+1.12%		+5.09%	+3.30%

Sep. 10	Weight-loss market to see 16 new drugs by 2029, report estimates	RE
Sep. 06	Basilea Pharmaceutica Secures $25 Million Milestone Payment from Pfizer	MT

PFIZER INC : UBS remains Neutral

July 31, 2024 at 01:59 pm EDT

UBS confirms his opinion on the stock and remains Neutral. Previously set at USD 30, the target price has been raised to USD 31.

Latest news about Pfizer, Inc.

Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
Basilea Pharmaceutica Secures $25 Million Milestone Payment from Pfizer	Sep. 06	MT
CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024	Sep. 05	CI
Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa	Sep. 05	CI
Transcript : Pfizer Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 08:30 AM	Sep. 04
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	Sep. 03	DJ
Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases	Sep. 03	CI
Vaxcyte's shares hit record high on early data on pneumococcal vaccine	Sep. 03	RE
Pfizer: new positive data in Lyme	Sep. 03	CF
Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data	Sep. 03	DJ
US will still pay at least twice as much after negotiating drug prices	Sep. 03	RE
Valneva, Pfizer's Second Lyme Disease Booster Shot Shows Antibody Response in Phase 2 Study	Sep. 03	MT
Valneva: new positive data in Lyme	Sep. 03	CF
Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate	Sep. 03	CI
Volcano Spring International Holdings Limited Announces Appointment of Zheng Jingwen as Non-Executive Director	Sep. 02	CI
Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine	Aug. 29	CI
Biden Commends Eli Lilly for Cheaper Zepbound Version, Vows to Negotiate Lower Obesity Drug Prices	Aug. 28	MT
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases Under Strategic Partnership with Pfizer	Aug. 28	CI
Delaware top court will hear drugmakers' appeal to end Zantac lawsuits	Aug. 27	RE
Pfizer: launch of a healthcare platform	Aug. 27	CF
Pfizer Launches Digital Healthcare Platform PfizerForAll in the US	Aug. 27	MT
Pfizer Inc. Launches PfizerForAll	Aug. 27	CI
Basilea's Cresemba Gains EU Approval for Pediatric Indications	Aug. 27	MT
Market on edge, anticipating Powell's play	Aug. 23
Analysis-Ozempic on Wall Street's list for 2027 Medicare drug negotiations	Aug. 23	RE

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).

Employees

88,000

Sector

Pharmaceuticals

Calendar

2024-10-28 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company